Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, announced it has entered into a definitive agreement to be acquired by AstraZeneca. The proposed acquisition...

Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, announced it has entered into a definitive agreement to be acquired by AstraZeneca. The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and…

---

View Entire Post